Showing 17,241 - 17,260 results of 106,247 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( e ((non decrease) OR (point decrease)) ))', query time: 1.09s Refine Results
  1. 17241

    DataSheet1_Refinement of SARS-CoV-2 envelope protein structure in a native-like environment by molecular dynamics simulations.docx by Rui Yang (293531)

    Published 2022
    “…<p>COVID-19 has become an unprecedented threat to human health. The SARS-CoV-2 envelope (E) protein plays a critical role in the viral maturation process and pathogenesis. …”
  2. 17242

    Data_Sheet_2_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.pdf by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”
  3. 17243
  4. 17244

    Table_5_Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study.docx by Xiaolin Pang (6566882)

    Published 2021
    “…</p>Conclusion<p>Radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates. The restaging LLNs with short axis ≥5 mm is a predictor of poor prognosis.…”
  5. 17245

    Data_Sheet_1_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.PDF by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”
  6. 17246

    DataSheet_1_Myricetin, the Main Flavonoid in Syzygium cumini Leaf, Is a Novel Inhibitor of Platelet Thiol Isomerases PDI and ERp5.docx by Renato Simões Gaspar (8384040)

    Published 2020
    “…Additionally, myricetin is a novel inhibitor of ERp5 and PDI, unveiling a new therapeutic perspective for the treatment of thrombotic disorders.…”
  7. 17247

    Influence of Sb<sup>5+</sup> as a Double Donor on Hematite (Fe<sup>3+</sup>) Photoanodes for Surface-Enhanced Photoelectrochemical Water Oxidation by Alagappan Annamalai (1542619)

    Published 2018
    “…In the presence of Sb<sup>5+</sup> states in Sb-doped Fe<sub>2</sub>O<sub>3</sub> photoanodes, as confirmed by X-ray photoelectron spectroscopy, we observed a 10-fold increase in carrier concentration (1.1 × 10<sup>20</sup> vs 1.3 × 10<sup>19</sup> cm<sup>–3</sup>) and decreased photoanode/electrolyte charge transfer resistance (∼990 vs ∼3700 Ω). …”
  8. 17248

    DataSheet_1_Myricetin, the Main Flavonoid in Syzygium cumini Leaf, Is a Novel Inhibitor of Platelet Thiol Isomerases PDI and ERp5.docx by Renato Simões Gaspar (8384040)

    Published 2020
    “…Additionally, myricetin is a novel inhibitor of ERp5 and PDI, unveiling a new therapeutic perspective for the treatment of thrombotic disorders.…”
  9. 17249

    Data_Sheet_1_Nitrogen and Phosphorus Retranslocation of Leaves and Stemwood in a Mature Eucalyptus Forest Exposed to 5 Years of Elevated CO2.docx by Kristine Y. Crous (6758423)

    Published 2019
    “…Given differences in how N and P are used by plants, we asked if their stoichiometry in leaves and wood was maintained or altered in a long-term elevated CO<sub>2</sub> experiment in a mature Eucalyptus forest on a low P soil (EucFACE). …”
  10. 17250

    Table_5_A comparative study on photosynthetic characteristics and flavonoid metabolism between Camellia petelotii (Merr.) Sealy and Camellia impressinervis Chang &Liang.xls by Xin Huang (11077)

    Published 2022
    “…Photodamage led to decreased photosynthesis, as shown by repressed transcript abundance for photosystem II genes psbA, B, C, O, and Q, photosystem I genes psaB, D, E, H, and N, electron transfer genes petE and F, and ATP synthesis genes ATPF1A and ATPF1B. …”
  11. 17251

    Table_5_A comparative study on photosynthetic characteristics and flavonoid metabolism between Camellia petelotii (Merr.) Sealy and Camellia impressinervis Chang &Liang.xls by Xin Huang (11077)

    Published 2022
    “…Photodamage led to decreased photosynthesis, as shown by repressed transcript abundance for photosystem II genes psbA, B, C, O, and Q, photosystem I genes psaB, D, E, H, and N, electron transfer genes petE and F, and ATP synthesis genes ATPF1A and ATPF1B. …”
  12. 17252
  13. 17253

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  14. 17254

    Table_5_A comparative study on photosynthetic characteristics and flavonoid metabolism between Camellia petelotii (Merr.) Sealy and Camellia impressinervis Chang &Liang.xls by Xin Huang (11077)

    Published 2022
    “…Photodamage led to decreased photosynthesis, as shown by repressed transcript abundance for photosystem II genes psbA, B, C, O, and Q, photosystem I genes psaB, D, E, H, and N, electron transfer genes petE and F, and ATP synthesis genes ATPF1A and ATPF1B. …”
  15. 17255

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  16. 17256

    Image_5_Smallholder Coffee in the Global Economy—A Framework to Explore Transformation Alternatives of Traditional Agroforestry for Greater Economic, Ecological, and Livelihood Via... by Pablo Siles (12453132)

    Published 2022
    “…<p>Sixty percent of global coffee is produced from farms of <5 ha. Studies show that returns from such farms do not generate a living income for producers or workers threatening supplies. …”
  17. 17257

    Image_5_Dietary patterns suggest that dark chocolate intake may have an inhibitory effect on oral cancer: a Mendelian randomization study.jpeg by Hongwei Wang (151141)

    Published 2024
    “…After using multivariable MR to adjust for serum caffeine, linoleate, theophylline, and theobromine metabolism levels, consuming dark chocolate was unrelated to a decreased risk of OC. After adjusting each serum metabolite individually, the observed p-values deviated from the original values to varying degrees, indicating that the components of dark chocolate could have different effects. …”
  18. 17258

    Image_5_Dietary patterns suggest that dark chocolate intake may have an inhibitory effect on oral cancer: a Mendelian randomization study.jpeg by Hongwei Wang (151141)

    Published 2024
    “…After using multivariable MR to adjust for serum caffeine, linoleate, theophylline, and theobromine metabolism levels, consuming dark chocolate was unrelated to a decreased risk of OC. After adjusting each serum metabolite individually, the observed p-values deviated from the original values to varying degrees, indicating that the components of dark chocolate could have different effects. …”
  19. 17259

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2022
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  20. 17260